DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device (REheal)

DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device for Intracranial Aneurysms

To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.

Study Overview

• Status: Recruiting
• Conditions: Intracranial Aneurysm; Flow Diverter
• Intervention / Treatment: Device: Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device

Detailed Description

The purpose of the DERIVO® 2heal® trial is to conduct a post market clinical follow-up (PMCF) study of the use of the DERIVO® 2heal® Embolisation Device in clinical practice according to EU MDCGs guidance. The DERIVO® 2heal® Study is designed as a prospective, single-arm, multicenter, open-label, national study conducted in Germany with approximately 15 sites planned. The study aims to investigate potential residual risks associated with the use of the device and to update the clinical evaluation of the device in order to ensure the long-term safety and performance of the DERIVO® 2heal® Embolisation Device after its placing on the market. For this purpose, the DERIVO® 2heal® Study will systematically collect information on technical success, safety, and clinical success of treatment of intracranial aneurysms with DERIVO® 2heal® Embolisation Device in clinical practice.

The study duration is expected to be 36 months of enrolment and 12 months follow-up of patients. Up to 158 patients should be enroled at approx. 15 study sites in Germany.

Informed consent will be obtained from all patients prior to implantation of the DERIVO® 2heal® Embolisation Device. In exceptional cases, informed consent may be obtained after the intervention, as the study is purely data collection. It should be noted that the signed informed consent form must be obtained before recording of data in the study and prior any study-specific assessments. Informed consent process will be performed according to ICH-GCP standards. In case of emergency situations when the treatment needs to be performed immediately and informed consent cannot be given prior to the rescue treatment, the informed consent can be obtained retrospectively from the patient or patient's legal representative.

The analysis population will be consist of all patients enrolled who were treated with DERIVO® 2heal® Embolisation device or in whom an attempt of DERIVO® 2heal® Embolisation device implantation was made.

Personal data will be processed in accordance with the relevant national and international legislation and good clinical practice. Data will only be processed for the purpose of the PMCF study. Person-identifiable data will not leave the unit from which they originated, and for pseudonymized data, keys to identification numbers will be held confidentially by the responsible person. Individual patient's medical information will be recorded in the study only in pseudonymized form.

All data in this project are captured in eCRFs and stored into an electronic clinical database. Quality control and data validation procedures such as programmed automatic edit and consistency checks ensure data validity and accuracy immediately at the point of entry into this database. The database application which is used to capture electronic clinical trial data is protected from unauthorized access it is, among other features, access restricted, contains rights and roles functionalities, provides electronic authentication of data entries, maintains an electronic audit trail and provides appropriate data backup functionalities.

After data entry, study monitoring team will perform source data verification and issue monitoring queries directly in the database application.

The database will only be locked after all queries and discrepancies that may have occurred during data entry have been resolved. After database lock, data will be exported in an electronic format and transferred to the responsible biometrician for analysis. The locked database may also be used to generate subject listings and tabulations.

The results of the trial will be reported to the central Ethics Committees after the study was completed. By signing the protocol, the investigator agrees that the results of the clinical investigation may be used for publication. The investigator also agrees that is not permitted to publish any data related to the trial independent of the Sponsor.

• Study Type: Observational
• Enrollment (Estimated): 158

Contacts and Locations

• Study Contact: Name: Acandis GmbH; Phone Number: Tel: +49 7231 155 00 0; Email: info@acandis.com

Study Locations

• Germany
  • Augsburg, Germany
    • Recruiting
    • Universitätsklinikum Augsburg
    • Contact: Ansgar Berlis, Prof.
  • Berlin, Germany
    • Recruiting
    • Charité - Universitätsmedizin Berlin
    • Contact: George Bohner, Dr.
  • Bremerhaven, Germany
    • Recruiting
    • Klinikum Bremerhaven-Reinkenheide
    • Contact: Timo Phung, Dr.
  • Cologne, Germany
    • Recruiting
    • Universitätsklinikum Köln
    • Contact: Christoph Kabbasch, Prof.
  • Dresden, Germany
    • Recruiting
    • Universitätsklinikum Carl Gustav Carus Dresden
    • Contact: Johannes Gerber, Dr.
  • Düsseldorf, Germany
    • Recruiting
    • Universitätsklinikum Düsseldorf
    • Contact: Bernd Turowski, Prof.; Email: bernd.turowski@med.uni-duesseldorf.de
  • Essen, Germany
    • Recruiting
    • Universitätsklinikum Essen
    • Contact: Cornelius Deuschl, Dr.
  • Frankfurt am Main, Germany
    • Recruiting
    • Krankenhaus Nordwest Frankfurt
    • Contact: Ansgar Schütz, Dr.
  • Halle, Germany
    • Recruiting
    • Universitätsmedizin Halle
    • Contact: Stefan Schob, PD Dr.
  • Hamburg, Germany
    • Recruiting
    • Universitätsklinikum Hamburg-Eppendorf
    • Contact: Maxim Bester, PD Dr.
  • Kaiserslautern, Germany
    • Recruiting
    • Westpfalz-Klinikum Kaiserslautern
    • Contact: Andreas Simgen, Dr.
  • Magdeburg, Germany
    • Recruiting
    • Universitätsklinikum Magdeburg
    • Contact: Behme Daniel, Prof.; Email: daniel.behme@med.ovgu.de
  • Minden, Germany
    • Recruiting
    • Mühlenkreiskliniken | Johannes Wesling Klinikum Minden
    • Contact: Christoph Mönninghoff, Prof.
  • München, Germany
    • Recruiting
    • Technische Universität München
    • Contact: Tobias Boeckh-Behrens, Dr.
  • München, Germany
    • Recruiting
    • Ludwig-Maximilians-Universität München
    • Contact: Thomas Liebig, Prof.
  • Recklinghausen, Germany
    • Recruiting
    • Klinikum Vest - Knappschaftskrankenhaus Recklinghausen
    • Contact: Christian Loehr, Dr.
  • Solingen, Germany
    • Recruiting
    • Städtisches Klinikum Solingen
    • Contact: Hannes Nordmeyer, Dr.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients who were selected for flow diversion therapy and will be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to clinical routine.

Description

Inclusion Criteria:

• Patient to be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to IFU
• Age > 18 years
• Signed Informed Consent Form
• Patient scheduled to be treated for only one target aneurysm except multiple aneurysms located in the same target zone to be treated with one DERIVO® 2heal® Embolisation Device
• Effective use of antiplatelet medication confirmed by applicable testing method according to local standard

Exclusion Criteria:

• Previously treated aneurysms with flow diverter, stent or WEB device
• Treatment as preparation for the flow-diversion treatment does not lead to exclusion of the patient
• Patient with a ruptured aneurysm in the acute phase of bleeding
• Pre-treatment disability (mRS > 2)
• Aneurysms related to pre-existing arteriosclerotic vascular disease in the target vessel
• Contraindication against treatment with anti-platelet medication
• Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study
• Participating in another study

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary efficacy endpoint	• Rate of complete aneurysm occlusion	6 weeks +/- 3weeks; 6months +/- 3 months; 12months +/-3months
Primary safety endpoint	Stroke/Death Occurrence Percentage of subjects with major stroke in the territory of treated artery or neurological death post-procedure; Rate of device-related & procedure-related complications (e.g. ICH, in-stent stenosis, in-stent thrombosis)	12month ± 3month
Primary clinical endpoint	• Good Clinical outcome	6 weeks ± 3weeks; 6months ± 3 months; 12months ± 3months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary efficacy endpoint	Wall apposition of the flow-diverter(s) per patient as determined by the treating physician and the core-lab after treatment.Correct wall apposition in the parent vesselGap between FD and vessel wall < 25 % of vessel diameterGap between FD and vessel wall >25 % of vessel diameter; Stasis / flow changes in the aneurysm (O´Kelly Marotta Scale/Kamran grading scale)	Measured directly after treatment
Secondary safety endpoint	• Rate of participants (%) with significant parent artery stenosis (> 50%) or retreatment of the target aneurysm post-procedure	12months ± 3months

Collaborators and Investigators

• Sponsor: Acandis GmbH
• Investigators: Study Director: Behme Daniel, Prof., Universitätsklinikum Magdeburg

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2022
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: September 14, 2022
• First Submitted That Met QC Criteria: September 14, 2022
• First Posted (Actual): September 16, 2022

Study Record Updates

• Last Update Posted (Estimated): September 4, 2025
• Last Update Submitted That Met QC Criteria: August 27, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Aneurysm; DERIVO; DERIVO 2 Heal
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Intracranial Arterial Diseases; Aneurysm; Intracranial Aneurysm
• Other Study ID Numbers: REheal Version 1.3, 03.06.2025

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No